Ganeshsingh Thakur

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1546730/publications.pdf

Version: 2024-02-01

58	1,779	236925 25	289244 40
papers	citations	h-index	g-index

59	59	59	1563
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biological Psychiatry, 2018, 84, 722-733.	1.3	101
2	Ligand-Binding Architecture of Human CB2 Cannabinoid Receptor: Evidence for Receptor Subtype-Specific Binding Motif and Modeling GPCR Activation. Chemistry and Biology, 2008, 15, 1207-1219.	6.0	88
3	(-)-7â€²-Isothiocyanato-11-hydroxy-1â€²,1â€²-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor. Molecular Pharmacology, 2005, 68, 1623-1635.	2.3	86
4	Cannabilactones: A Novel Class of CB2 Selective Agonists with Peripheral Analgesic Activity. Journal of Medicinal Chemistry, 2007, 50, 6493-6500.	6.4	86
5	Latest advances in cannabinoid receptor agonists. Expert Opinion on Therapeutic Patents, 2009, 19, 1647-1673.	5.0	79
6	Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. ACS Chemical Neuroscience, 2017, 8, 1188-1203.	3.5	78
7	CB1 Cannabinoid Receptor Ligands. Mini-Reviews in Medicinal Chemistry, 2005, 5, 631-640.	2.4	72
8	The Î±7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain. British Journal of Pharmacology, 2016, 173, 2506-2520.	5.4	64
9	Expeditious Synthesis, Enantiomeric Resolution, and Enantiomer Functional Characterization of		

#	Article	IF	Citations
19	The Activity of GAT107, an Allosteric Activator and Positive Modulator of Î±7 Nicotinic Acetylcholine Receptors (nAChR), Is Regulated by Aromatic Amino Acids That Span the Subunit Interface. Journal of Biological Chemistry, 2014, 289, 4515-4531.	3.4	36
20	Mass Spectrometry-based Proteomics of Human Cannabinoid Receptor 2: Covalent Cysteine 6.47(257)-Ligand Interaction Affording Megagonist Receptor Activation. Journal of Proteome Research, 2011, 10, 4789-4798.	3.7	35
21	Microwave-assisted expeditious and efficient synthesis of cyclopentene ring-fused tetrahydroquinoline derivatives using three-component Povarov reaction. Tetrahedron Letters, 2013, 54, 6592-6595.	1.4	34
22	Persistent activation of Î±7 nicotinic ACh receptors associated with stable induction of different desensitized states. British Journal of Pharmacology, 2018, 175, 1838-1854.	5.4	31
23	Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. ACS Chemical Neuroscience, 2016, 7, 776-798.	3.5	30
24	Controlled-Deactivation Cannabinergic Ligands. Journal of Medicinal Chemistry, 2013, 56, 10142-10157.	6.4	26
25	Probing the Carboxyester Side Chain in Controlled Deactivation (â^')-Î”⁸-Tetrahydrocannabinols. Journal of Medicinal Chemistry, 2015, 58, 665-681.	6.4	26
26	Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. Molecules, 2020, 25, 417.	3.8	26
27	Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structureâ€“Activity Relationship Studies. ACS Medicinal Chemistry Letters, 2019, 10, 1216-1221.	2.8	25
28	Allosteric Agonism of Î±7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site. Molecular Pharmacology, 2019, 95, 606-614.	2.3	24
29	The interaction between alpha 7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-Î± represents a new antinociceptive signaling pathway in mice. Experimental Neurology, 2017, 295, 194-201.	4.1	23
30	Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. Pharmacological Research, 2018, 129, 475-481.	7.1	23
31	Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. Neuropharmacology, 2021, 190, 108553.	4.1	22
32	TheIn VivoEffects of the CB₁-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 582-590.	1.4	21
33	Macroscopic and Microscopic Activation of Î±7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107. Molecular Pharmacology, 2019, 95, 43-61.	2.3	21
34	A concise methodology for the synthesis of (â^')-Î”9-tetrahydrocannabinol and (â^')-Î”9-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs. Tetrahedron, 2007, 63, 8112-8123.	1.9	20
35	The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents. Journal of Biological Chemistry, 2020, 295, 3614-3634.	3.4	20
36	Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. Journal of Medicinal Chemistry, 2021, 64, 8104-8126.	6.4	18

#	Article	IF	Citations
37	Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. Expert Opinion on Drug Discovery, 2016, 11, 1223-1237.	5.0	17
38	Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. Journal of Proteomics, 2002, 54, 415-422.	2.4	16
39	Hydrogen sulfide inhibits Kir2 and Kir3 channels by decreasing sensitivity to the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2). Journal of Biological Chemistry, 2018, 293, 3546-3561.	3.4	15
40	B-973, a Novel Î±7 nAChR Ago-PAM: Racemic and Asymmetric Synthesis, Electrophysiological Studies, and in Vivo Evaluation. ACS Medicinal Chemistry Letters, 2018, 9, 1144-1148.	2.8	14
41	Microwaveâ€accelerated Conjugate Addition of 2â€Arylindoles to Substituted Î²â€Nitrostyrenes in the Presence of Ammonium Trifluoroacetate: An Efficient Approach for the Synthesis of a Novel Class of CB1 Cannabinoid Receptor Allosteric Modulators. Journal of Heterocyclic Chemistry, 2017, 54, 2079-2084.	2.6	13
42	Design and Synthesis of Cannabinoid 1 Receptor (CB1R) Allosteric Modulators: Drug Discovery Applications. Methods in Enzymology, 2017, 593, 281-315.	1.0	12
43	Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. Frontiers in Molecular Neuroscience, 2019, 12, 257.	2.9	12
44	Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of Î±7 nAChR. Molecular Pharmacology, 2020, 98, 292-302.	2.3	12
45	Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant Î² Subunits Acquire Sensitivity to Î±7-Selective Positive Allosteric Modulators. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 252-268.	2.5	10
46	Allosterically Potentiated Î±7 Nicotinic Acetylcholine Receptors: Reduced Calcium Permeability and Current-Independent Control of Intracellular Calcium. Molecular Pharmacology, 2020, 98, 695-709.	2.3	10
47	The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome. Neuropharmacology, 2022, 205, 108897.	4.1	9
48	Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists. Journal of Medicinal Chemistry, 2021, 64, 3870-3884.	6.4	8
49	Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a Â-Opioid Agonist in THC-Treated Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 334-341.	2.5	7
50	Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110235.	4.8	7
51	A benzopyran with antiarrhythmic activity is an inhibitor of Kir3.1-containing potassium channels. Journal of Biological Chemistry, 2021, 296, 100535.	3.4	7
52	Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. ACS Chemical Neuroscience, 2017, 8, 1338-1347.	3.5	6
53	Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. Psychopharmacology, 2021, 238, 1087-1098.	3.1	6
54	Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. Bioorganic and Medicinal Chemistry, 2020, 28, 115727.	3.0	5

#	Article	IF	Citations
55	The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. IBRO Neuroscience Reports, 2022, 12, 121-130.	1.6	5
56	Stable desensitization of Î±7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site. European Journal of Pharmacology, 2021, 905, 174179.	3.5	4
57	Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorganic and Medicinal Chemistry, 2021, 50, 116421.	3.0	4
58	A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Î” 9 -THC in rats. Pharmacology Biochemistry and Behavior, 2016, 148, 46-52.	2.9	3